Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: a randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU)
Raja Dhar, John Kirkpatrick, Laura Gilbert, Arjun Khanna, Mahavir Madhavdas Modi, Rakesh K. Chawla, Sonia Dalal, Venkata Nagarjuna Maturu, Marcel Stern, Oliver Keppler, Ratko Djukanović, Stephan Gadola
doi: https://doi.org/10.1101/2022.01.30.22269685
Raja Dhar
1Department of Pulmonology, CMRI Hospital, Kolkata, India
John Kirkpatrick
2John Kirkpatrick, MSc, Independent Researcher, Cambridgeshire, UK
Laura Gilbert
3Laura Gilbert, Rutherford Research, Hampshire, UK
Arjun Khanna
4Pulmonary and Critical care medicine, Yashoda Superspeciality Hospital, Kaushambi, Ghaziabad, UP, India
Mahavir Madhavdas Modi
5Ruby Hall Clinic, Pune, Maharashtra, India
Rakesh K. Chawla
6Saroj Super Speciality Hospital and Jaipur Golden Hospital, Dept of Respiratory Medicine, Critical Care and Sleep Disorders, New Delhi, India
Sonia Dalal
7Sterling Hospital and Kalyan Hospital, Vadodara, India
Venkata Nagarjuna Maturu
8Yashoda Hospitals, Hyderabad, India
Marcel Stern
9Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany
Oliver Keppler
9Max von Pettenkofer Institute and Gene Center, Virology, National Reference Center for Retroviruses, Faculty of Medicine, LMU München, Munich, Germany
Ratko Djukanović
10Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, Southampton, UK
Stephan Gadola
10Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, and NIHR Southampton Biomedical Research Centre, Southampton, UK
11Rheumatology and Pain Medicine, Bethesda Hospital, Basel, Switzerland
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article usage
Posted February 22, 2022.
Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: a randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU)
Raja Dhar, John Kirkpatrick, Laura Gilbert, Arjun Khanna, Mahavir Madhavdas Modi, Rakesh K. Chawla, Sonia Dalal, Venkata Nagarjuna Maturu, Marcel Stern, Oliver Keppler, Ratko Djukanović, Stephan Gadola
medRxiv 2022.01.30.22269685; doi: https://doi.org/10.1101/2022.01.30.22269685
Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: a randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU)
Raja Dhar, John Kirkpatrick, Laura Gilbert, Arjun Khanna, Mahavir Madhavdas Modi, Rakesh K. Chawla, Sonia Dalal, Venkata Nagarjuna Maturu, Marcel Stern, Oliver Keppler, Ratko Djukanović, Stephan Gadola
medRxiv 2022.01.30.22269685; doi: https://doi.org/10.1101/2022.01.30.22269685
Subject Area
Subject Areas
- Addiction Medicine (346)
- Allergy and Immunology (666)
- Anesthesia (181)
- Cardiovascular Medicine (2636)
- Dermatology (223)
- Emergency Medicine (398)
- Epidemiology (12206)
- Forensic Medicine (10)
- Gastroenterology (756)
- Genetic and Genomic Medicine (4081)
- Geriatric Medicine (387)
- Health Economics (679)
- Health Informatics (2639)
- Health Policy (1002)
- Hematology (362)
- HIV/AIDS (849)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (433)
- Neurology (3861)
- Nursing (209)
- Nutrition (575)
- Oncology (2017)
- Ophthalmology (584)
- Orthopedics (240)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (472)
- Pediatrics (1113)
- Primary Care Research (450)
- Public and Global Health (6512)
- Radiology and Imaging (1396)
- Respiratory Medicine (871)
- Rheumatology (403)
- Sports Medicine (342)
- Surgery (442)
- Toxicology (52)
- Transplantation (185)
- Urology (165)